Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Consolidated Net Income (2020 - 2025)

Vivos Therapeutics' Consolidated Net Income history spans 6 years, with the latest figure at -$7.0 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at -$7.0 million for Q4 2025, down 145.99% from a year ago — trailing twelve months through Dec 2025 was -$21.2 million (down 90.65% YoY), and the annual figure for FY2025 was -$21.2 million, down 90.64%.
  • Consolidated Net Income for Q4 2025 was -$7.0 million at Vivos Therapeutics, down from -$5.4 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $17.9 million in Q4 2022 to a low of -$7.0 million in Q2 2022.
  • The 5-year median for Consolidated Net Income is -$4.0 million (2021), against an average of -$2.3 million.
  • Peak annual rise in Consolidated Net Income hit 306.13% in 2021, while the deepest fall reached 197.29% in 2021.
  • Year by year, Consolidated Net Income stood at $12.9 million in 2021, then skyrocketed by 38.27% to $17.9 million in 2022, then tumbled by 123.85% to -$4.3 million in 2023, then skyrocketed by 33.62% to -$2.8 million in 2024, then tumbled by 145.99% to -$7.0 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$7.0 million, -$5.4 million, and -$5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.